JOP20240197A1 - أشكال متعددة من الأتيكابرانت للاستخدام في علاج اضطراب الاكتئاب الشديد - Google Patents
أشكال متعددة من الأتيكابرانت للاستخدام في علاج اضطراب الاكتئاب الشديدInfo
- Publication number
- JOP20240197A1 JOP20240197A1 JOJO/P/2024/0197A JOP20240197A JOP20240197A1 JO P20240197 A1 JOP20240197 A1 JO P20240197A1 JO P20240197 A JOP20240197 A JO P20240197A JO P20240197 A1 JOP20240197 A1 JO P20240197A1
- Authority
- JO
- Jordan
- Prior art keywords
- atecaprant
- crystalline
- depressive disorder
- major depressive
- amorphous forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317475P | 2022-03-07 | 2022-03-07 | |
| PCT/IB2023/052088 WO2023170550A1 (en) | 2022-03-07 | 2023-03-06 | Polymorph forms of aticaprant for use in treating major depressive disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240197A1 true JOP20240197A1 (ar) | 2024-09-05 |
Family
ID=85706849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0197A JOP20240197A1 (ar) | 2022-03-07 | 2024-09-05 | أشكال متعددة من الأتيكابرانت للاستخدام في علاج اضطراب الاكتئاب الشديد |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11998524B2 (https=) |
| EP (1) | EP4489747A1 (https=) |
| JP (1) | JP2025508051A (https=) |
| KR (1) | KR20240156409A (https=) |
| CN (1) | CN119156211A (https=) |
| AU (1) | AU2023232536A1 (https=) |
| CA (1) | CA3254365A1 (https=) |
| CL (1) | CL2024002627A1 (https=) |
| CO (1) | CO2024012158A2 (https=) |
| IL (1) | IL315409A (https=) |
| JO (1) | JOP20240197A1 (https=) |
| MX (1) | MX2024010980A (https=) |
| TW (1) | TW202345796A (https=) |
| WO (1) | WO2023170550A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| TR200103237T2 (tr) | 1999-05-12 | 2002-04-22 | F. Hoffmann-La Roche Ag | İmidazodiazepin türevi |
| US20020052365A1 (en) | 2000-10-05 | 2002-05-02 | Mohler Hanns | Selective anxiolytic therapeutic agents |
| JP2004518654A (ja) | 2000-12-21 | 2004-06-24 | ザ マクレーン ホスピタル コーポレーション | 鬱病の治療法 |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| DE60319812T2 (de) | 2002-03-28 | 2009-04-23 | Wisys Technology Foundation, Inc., Madison | Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen |
| KR101025633B1 (ko) | 2002-09-19 | 2011-03-30 | 일라이 릴리 앤드 캄파니 | 오피오이드 수용체 안타고니스트로서의 디아릴 에테르 |
| ATE406360T1 (de) | 2003-03-07 | 2008-09-15 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| EP1613597B1 (en) | 2003-03-07 | 2007-11-07 | Eli Lilly and Company | 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| CA2549009A1 (en) | 2003-12-12 | 2005-07-07 | Eli Lilly And Company | Opioid receptor antagonists |
| ES2390459T3 (es) | 2003-12-22 | 2012-11-13 | Eli Lilly And Company | Antagonistas de receptores de opioides |
| DE602005022572D1 (de) | 2004-03-12 | 2010-09-09 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| EP1729759A4 (en) | 2004-03-12 | 2008-04-02 | Mclean Hospital Corp | SALVINORINE DERIVATIVES AND ITS USES |
| ATE399164T1 (de) | 2004-03-12 | 2008-07-15 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| DE602005012380D1 (de) | 2004-03-15 | 2009-03-05 | Lilly Co Eli | 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit |
| EP1735268B1 (en) | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Opioid receptor antagonists |
| WO2007067714A2 (en) | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| JP5128578B2 (ja) | 2006-04-04 | 2013-01-23 | エモディス ゲーエムベーハー | 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 |
| EP2049481A2 (en) | 2006-08-09 | 2009-04-22 | SmithKline Beecham Corporation | Novel compounds as antagonists or inverse agonists for opioid receptors |
| EP2054383A2 (en) | 2006-08-09 | 2009-05-06 | SmithKline Beecham Corporation | Novel compounds as antagonists or inverse agonists at opioid receptors |
| KR20090051778A (ko) | 2006-09-08 | 2009-05-22 | 화이자 프로덕츠 인코포레이티드 | 다이아릴 에터 유도체 및 이의 용도 |
| JP5345637B2 (ja) | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
| WO2012016569A1 (en) | 2010-08-05 | 2012-02-09 | Conrig Pharma Aps | Deuterated tandospirone derivatives as 5-ht1a receptor agonists |
| ES2631607T3 (es) | 2011-12-09 | 2017-09-01 | Research Triangle Institute, International | 4-Arilpiperazinas 1-sustituidas como antagonistas del receptor opioide kappa |
| ES2694352T3 (es) | 2013-12-20 | 2018-12-20 | H. Lundbeck A/S | Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas |
| WO2016156396A1 (en) | 2015-03-30 | 2016-10-06 | University Of Innsbruck | Diphenethylamine derivatives which are inter alia useful as analgesics and methods for their production |
| US10709685B2 (en) | 2015-05-28 | 2020-07-14 | Georgetown University | Use of methadone metabolites for treatment of anxiety and depression |
| EP3468540A4 (en) | 2016-06-13 | 2020-03-18 | Board Of Regents Of the University Of Texas System | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN |
| US20190240293A1 (en) | 2016-07-26 | 2019-08-08 | Flagship Pioneering Innovations V, Inc. | Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response |
| US11292783B2 (en) | 2016-09-16 | 2022-04-05 | Research Triangle Institute | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| AU2018234931B2 (en) | 2017-03-17 | 2022-05-26 | Blackthorn Therapeutics, Inc. | Kappa opioid receptor antagonists and products and methods related thereto |
| PH12018000077B1 (en) | 2017-07-05 | 2021-07-09 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| US20190255036A1 (en) | 2018-02-16 | 2019-08-22 | Alexander Kariman | Compound and method for reducing neuropathic pain and depression |
| JP7416751B2 (ja) | 2018-03-23 | 2024-01-17 | ユニバーシティ オブ カンザス | 環状テトラペプチド類似体 |
| US11491144B2 (en) | 2018-03-30 | 2022-11-08 | The Florida State University Research Foundation, Incorporated | Methods of treating fragile X mental retardation syndrome |
| EP3870030A4 (en) | 2018-10-23 | 2022-08-03 | Blackthorn Therapeutics, Inc. | SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS AND STRATIFICATION OF PATIENTS |
| US20200171025A1 (en) | 2018-11-29 | 2020-06-04 | Srinivasa Rao Parella | Pharmaceutical composition comprising brexpiprazole and process for preparation thereof |
| US11266627B1 (en) * | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| PH12023552963A1 (en) * | 2021-05-04 | 2024-03-11 | Janssen Pharmaceuticals Inc | Compositions and methods for the treatment of depression |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| AU2023231493A1 (en) | 2022-03-07 | 2024-10-24 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
-
2023
- 2023-03-06 WO PCT/IB2023/052088 patent/WO2023170550A1/en not_active Ceased
- 2023-03-06 KR KR1020247033176A patent/KR20240156409A/ko active Pending
- 2023-03-06 US US18/178,961 patent/US11998524B2/en active Active
- 2023-03-06 IL IL315409A patent/IL315409A/en unknown
- 2023-03-06 JP JP2024553358A patent/JP2025508051A/ja active Pending
- 2023-03-06 EP EP23712343.5A patent/EP4489747A1/en active Pending
- 2023-03-06 AU AU2023232536A patent/AU2023232536A1/en active Pending
- 2023-03-06 CA CA3254365A patent/CA3254365A1/en active Pending
- 2023-03-06 CN CN202380038808.6A patent/CN119156211A/zh active Pending
- 2023-03-06 TW TW112108148A patent/TW202345796A/zh unknown
-
2024
- 2024-05-31 US US18/679,720 patent/US12171743B2/en active Active
- 2024-09-02 CL CL2024002627A patent/CL2024002627A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0197A patent/JOP20240197A1/ar unknown
- 2024-09-06 CO CONC2024/0012158A patent/CO2024012158A2/es unknown
- 2024-09-06 MX MX2024010980A patent/MX2024010980A/es unknown
- 2024-12-23 US US18/991,891 patent/US20250325515A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023232536A1 (en) | 2024-10-24 |
| US20230277499A1 (en) | 2023-09-07 |
| US11998524B2 (en) | 2024-06-04 |
| IL315409A (en) | 2024-11-01 |
| CL2024002627A1 (es) | 2025-01-24 |
| CN119156211A (zh) | 2024-12-17 |
| KR20240156409A (ko) | 2024-10-29 |
| US12171743B2 (en) | 2024-12-24 |
| WO2023170550A1 (en) | 2023-09-14 |
| CO2024012158A2 (es) | 2024-09-30 |
| JP2025508051A (ja) | 2025-03-21 |
| CA3254365A1 (en) | 2023-09-14 |
| EP4489747A1 (en) | 2025-01-15 |
| US20240316003A1 (en) | 2024-09-26 |
| US20250325515A1 (en) | 2025-10-23 |
| MX2024010980A (es) | 2024-12-06 |
| TW202345796A (zh) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20240197A1 (ar) | أشكال متعددة من الأتيكابرانت للاستخدام في علاج اضطراب الاكتئاب الشديد | |
| EP4473970A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS | |
| DE502007002101D1 (de) | Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| BR112022013646A2 (pt) | Método de tratamento de esplenomegalia | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| EA201991933A1 (ru) | Лечение гингивита | |
| EA202290048A1 (ru) | Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| EP4431098A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF ALPORT SYNDROME | |
| JOP20250174A1 (ar) | بروتينات اندماج il-12 fc | |
| WO2023043870A8 (en) | Chewing gum formulation of lsd and methods of use thereof | |
| EP4285910A4 (en) | Pharmaceutical composition for treatment of neuroinflammation, comprising eleutheroside b as active ingredient | |
| PH12018501769A1 (en) | Medicament for treatment of diabetic foot infections | |
| EP4197554A4 (en) | COMBINATION DRUG FOR THE TREATMENT OF SOFT TISSUE SARCOMA | |
| MX2025000682A (es) | Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma | |
| EA201991530A1 (ru) | Композиции и способы лечения биопленок | |
| EP4582087A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LYMPHOMA | |
| WO2020061067A8 (en) | Compositions and methods for treating bone injury | |
| EP4452295A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRAL INFECTIONS | |
| EP4201406A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES COMPRISING ABEMACICLIB AS ACTIVE INGREDIENT |